Genmab — Januar 2013
-
gemiat. vi sidder stort set og superviser GSK corporate information
-
De skulle betale os big bucks!
-
-
Siger de noget fornuftigt om RG1512?
-
ok, jeg kan jo også selv læse det
-
-
http://www.roche.com/investors/ir_update/inv-update-2013-01-31.htm ikke mange oplysninger !
-
Det står til primary completion 2021 på clinicaltrials
-
Positive resultater for Genmab-konkurrent
En lægemiddelskandidat fra medicinalgiganten Roche mod en særlig form for leukæmi har opfyldt det primære end-point i et nyt fase 3 studie. Danske Genmab har allerede et middel mod sygdommen på markedet, dog kun i 3.-linjebehandling.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind